Matches in SemOpenAlex for { <https://semopenalex.org/work/W2276883304> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2276883304 endingPage "426" @default.
- W2276883304 startingPage "423" @default.
- W2276883304 abstract "Objective To investigate the efficacy of combined hyperfractionated radiation therapy (HFX RT) plus accelerated HFX RT and concomitant chemotherapy (CHT) in stage ⅢA or ⅢB non-small-cell lung cancer (NSCLC) compared with HFX RT alone. Methods From August 1998 to December 2001, 56 patients with NSCLC were randomized into the following groups: HFX RT alone group (group Ⅰ, n=28), HFX RT with 1.2 Gy twice daily to a total dose of 45.6 Gy, followed by accelerated HFX RT with 1.6 Gy twice daily, the total planned radiation dose was 68.0 Gy in tumour; HFX RT/CHT concomitant group (group Ⅱ, n=28), same RT with CHT consisting of 20 mg/m2 of cisplatin (DDP) on days 1 to 3 and 50 mg/m2 of etoposide (VP 16) on days 1 to 3, repeated every two weeks during the RT course. Results The overall response rate was 78.6% in group Ⅱ, including 10 patients with complete response and 12 with partial response; 39.3% in group Ⅰ, including 11 patients with partial response. Group Ⅱ had a higher overall response rate compared to Group Ⅰ (P=0.003). The median survival time was 16 months for group Ⅱ, 13 months for group Ⅰ. There was a significant difference in the median survival time between two groups (P= 0.000 3 ). Group Ⅱ (57.1%) had a lower distant metastasis rate compared with group Ⅰ (85.7%) (P= 0.018 ). Patients in group Ⅱ showed a higher incidence of acute and/or late high-grade toxicity (hematologic toxicity, esophagitis, late lung toxicity) compared with group Ⅰ patients, but no significant difference was observed between the two groups. Conclusion The HFX RT plus accelerated HFX RT and concomitant PDD/VP-16 CHT is tolerable and substantially increases the response rate and prolongs survival in ⅢA/ⅢB NSCLC patients.DOI: 10.3779/j.issn.1009-3419.2002.06.08" @default.
- W2276883304 created "2016-06-24" @default.
- W2276883304 creator A5003402829 @default.
- W2276883304 creator A5016944139 @default.
- W2276883304 creator A5030221922 @default.
- W2276883304 creator A5042958093 @default.
- W2276883304 creator A5063300954 @default.
- W2276883304 creator A5073606490 @default.
- W2276883304 date "2002-12-20" @default.
- W2276883304 modified "2023-09-28" @default.
- W2276883304 title "[Randomized trial of hyperfractionated plus accelerated hyperfractionated radiation therapy with or without concomitant chemotherapy for stage IIIA/IIIB non-small-cell lung cancer:A preliminary result]." @default.
- W2276883304 doi "https://doi.org/10.3779/j.issn.1009-3419.2002.06.08" @default.
- W2276883304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21333221" @default.
- W2276883304 hasPublicationYear "2002" @default.
- W2276883304 type Work @default.
- W2276883304 sameAs 2276883304 @default.
- W2276883304 citedByCount "0" @default.
- W2276883304 crossrefType "journal-article" @default.
- W2276883304 hasAuthorship W2276883304A5003402829 @default.
- W2276883304 hasAuthorship W2276883304A5016944139 @default.
- W2276883304 hasAuthorship W2276883304A5030221922 @default.
- W2276883304 hasAuthorship W2276883304A5042958093 @default.
- W2276883304 hasAuthorship W2276883304A5063300954 @default.
- W2276883304 hasAuthorship W2276883304A5073606490 @default.
- W2276883304 hasConcept C126322002 @default.
- W2276883304 hasConcept C126894567 @default.
- W2276883304 hasConcept C143998085 @default.
- W2276883304 hasConcept C168563851 @default.
- W2276883304 hasConcept C2776256026 @default.
- W2276883304 hasConcept C2776694085 @default.
- W2276883304 hasConcept C2778119113 @default.
- W2276883304 hasConcept C2779134260 @default.
- W2276883304 hasConcept C2779384505 @default.
- W2276883304 hasConcept C2779920096 @default.
- W2276883304 hasConcept C29730261 @default.
- W2276883304 hasConcept C43270747 @default.
- W2276883304 hasConcept C509974204 @default.
- W2276883304 hasConcept C71924100 @default.
- W2276883304 hasConcept C90924648 @default.
- W2276883304 hasConceptScore W2276883304C126322002 @default.
- W2276883304 hasConceptScore W2276883304C126894567 @default.
- W2276883304 hasConceptScore W2276883304C143998085 @default.
- W2276883304 hasConceptScore W2276883304C168563851 @default.
- W2276883304 hasConceptScore W2276883304C2776256026 @default.
- W2276883304 hasConceptScore W2276883304C2776694085 @default.
- W2276883304 hasConceptScore W2276883304C2778119113 @default.
- W2276883304 hasConceptScore W2276883304C2779134260 @default.
- W2276883304 hasConceptScore W2276883304C2779384505 @default.
- W2276883304 hasConceptScore W2276883304C2779920096 @default.
- W2276883304 hasConceptScore W2276883304C29730261 @default.
- W2276883304 hasConceptScore W2276883304C43270747 @default.
- W2276883304 hasConceptScore W2276883304C509974204 @default.
- W2276883304 hasConceptScore W2276883304C71924100 @default.
- W2276883304 hasConceptScore W2276883304C90924648 @default.
- W2276883304 hasIssue "6" @default.
- W2276883304 hasLocation W22768833041 @default.
- W2276883304 hasLocation W22768833042 @default.
- W2276883304 hasOpenAccess W2276883304 @default.
- W2276883304 hasPrimaryLocation W22768833041 @default.
- W2276883304 hasVolume "5" @default.
- W2276883304 isParatext "false" @default.
- W2276883304 isRetracted "false" @default.
- W2276883304 magId "2276883304" @default.
- W2276883304 workType "article" @default.